cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Humanigen Inc
17 own
17 watching
Current Price
$0.15
$0
(1.7%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
17.83M
52-Week High
52-Week High
3.25
52-Week Low
52-Week Low
0.0924
Average Volume
Average Volume
0.49M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization17.83M
icon52-Week High3.25
icon52-Week Low0.0924
iconAverage Volume0.49M
iconDividend Yield--
iconP/E Ratio--
What does the Humanigen Inc do?
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ‘cytokine storm . Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.
Read More
How much money does Humanigen Inc make?
News & Events about Humanigen Inc.
PR Newswire
3 months ago
Thinking about buying stock in Sidus Space, Nu Holdings, Vallon Pharmaceuticals, Bed Bath & Beyond, or Humanigen? Thinking about buying stock in Sidus Space, Nu Holdings, Vallon Pharmaceuticals, Bed Bath & Beyond, or Humanigen? PR Newswire NEW YORK, Feb. 15, 2023 NEW YORK, Feb. 15...
PR Newswire
4 months ago
Thinking about buying stock in Mullen Automotive, Humanigen, Vyant Bio, IQIYI, or Lucira Health? Thinking about buying stock in Mullen Automotive, Humanigen, Vyant Bio, IQIYI, or Lucira Health? PR Newswire NEW YORK, Jan. 5, 2023 NEW YORK, Jan. 5, 2023 /PRNewswire/ -- InvestorsObserverissues...
Business Wire
7 months ago
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Humanigen, Inc. (Humanigen or the Company) (NASDAQ: HGEN) and certain of its officers on behalf of all persons and entities that purchased, or otherwise acquired...
Globe Newswire
7 months ago
NEW YORK, Oct. 25, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 16, 2020 and July 12, 2022, both dates inclusive (the Class Period) of the important October 25, 2022 lead plaintiff ...
Globe Newswire
7 months ago
NEW YORK, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links belowor you may contact ...
Frequently Asked Questions
Frequently Asked Questions
What is Humanigen Inc share price today?
plus_minus_icon
Can Indians buy Humanigen Inc shares?
plus_minus_icon
How can I buy Humanigen Inc shares from India?
plus_minus_icon
Can Fractional shares of Humanigen Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Humanigen Inc stocks?
plus_minus_icon
What is today’s traded volume of Humanigen Inc?
plus_minus_icon
What is today’s market capitalisation of Humanigen Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Humanigen Inc?
plus_minus_icon
What percentage is Humanigen Inc down from its 52-Week High?
plus_minus_icon
What percentage is Humanigen Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.15
$0
(1.7%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
ONCTERNAL THERAPEUTICS INC
ONCTERNAL THERAPEUTICS INC
$0.30
$0.01 (1.83 %)
Finch Therapeutics Group Inc
Finch Therapeutics Group Inc
$0.28
$-0.01 (-2.89 %)
Angion Biomedica Corp
Angion Biomedica Corp
$0.95
$0.10 (11.75 %)
I-Mab
I-Mab
$3.11
$0.12 (4.01 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
ONCTERNAL THERAPEUTICS INC
ONCTERNAL THERAPEUTICS INC
$0.30
$0.01 (1.83 %)
Finch Therapeutics Group Inc
Finch Therapeutics Group Inc
$0.28
$-0.01 (-2.89 %)
Angion Biomedica Corp
Angion Biomedica Corp
$0.95
$0.10 (11.75 %)
I-Mab
I-Mab
$3.11
$0.12 (4.01 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00